With respect to the initial reason for consultation, we classified the CYP19A1 variant as a VUS for polycystic ovarian syndrome and counseled the consultand that we could not be certain whether this rare variant had any effect on her overall health, on her unusual number of adverse reactions to medications, or on her polycystic ovarian syndrome. This evidence concerns the gene CYP19A1 and polycystic ovary syndrome.